AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
KEYWORDS:
  • neurology
  • cladribine
  • orphan autoimmune diseases
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (12 releases)

AOP Orphan Pharmaceuticals AG (AOP Orphan) and Chord Therapeutics (Chord) step into a new partnership to develop CRD1 for treatment of orphan autoimmune diseases. [more]

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217010 Science/Technology, Health/Medicine
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217008 Science/Technology, Health/Medicine
AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
2018-12-03, pts20181203046 Health/Medicine, Products/Innovations
AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
2018-03-22, pts20180322023 Products/Innovations, Science/Technology
AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations

1 2 Next »